ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Louagie, Y. A.
Right arrow Articles by Schoevaerdts, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Louagie, Y. A.
Right arrow Articles by Schoevaerdts, J. C.

The Annals of Thoracic Surgery, Vol 56, 931-936, Copyright © 1993 by The Society of Thoracic Surgeons


ARTICLES

Mitral valve Carpentier-Edwards bioprosthetic replacement, thromboembolism, and anticoagulants

YA Louagie, J Jamart, P Eucher, M Buche and JC Schoevaerdts
Division of Cardiovascular and Thoracic Surgery, University Hospital of Mont Godinne (Yvoir), Belgium.

Patients undergoing mitral valve replacement (MVR) using a bioprosthesis are frequently placed on long-term anticoagulant treatment, and thereby lose the main advantage conferred by the bioprosthesis. To assess predictive factors of the need for long-term anticoagulant treatment, 100 consecutive patients surviving bioprosthetic MVR between 1977 and 1987 were followed up. The estimated thromboembolism-free survival was 88.9% +/- 3.6% after 6 years of follow-up. Preoperative risk factors for thromboembolism were supraventricular arrhythmia (p = 0.013) and a history of thromboembolism (p = 0.039). Among the preoperative and postoperative factors, only postoperative rhythm significantly influenced (p = 0.007) the thromboembolism-free survival, as determined by Cox regression analysis. Permanent anticoagulant treatment was instituted in 39 patients. Preoperative and peroperative risk factors associated with the need for long-term anticoagulant treatment, as evidenced by Fisher linear discriminant analysis, were supraventricular arrhythmia (p < 0.001), septal myotomy (p = 0.013), and predominant mitral stenosis (p = 0.013). Thus, in those patients with predominant mitral stenosis and supraventricular arrhythmia preoperatively, the subsequent need for permanent postoperative anticoagulant treatment is high, and the implantation of a mechanical valve is therefore recommended, providing there are no strict contraindications to anticoagulant treatment.


This article has been cited by other articles:


Home page
ChestHome page
D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker
Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 593S - 629S.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Nowell, E. Wilton, H. Markus, and M. Jahangiri
Antithrombotic therapy following bioprosthetic aortic valve replacement
Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 578 - 585.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T.M. Sundt, K.J. Zehr, J.A. Dearani, R.C. Daly, C.J. Mullany, C.G.A. McGregor, F.J. Puga, T.A. Orszulak, and H.V. Schaff
Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1024 - 1031.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker
Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 457S - 482S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P. D. Stein, J. S. Alpert, H. I. Bussey, J. E. Dalen, and A. G.G. Turpie
Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves
Chest, January 1, 2001; 119(1_suppl): 220S - 227S.
[Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
M. Emir, G. Uzunonat, B. Yamak, A T. Ulus, M K. Gol, Z. Iscan, S F. Katircioglu, B. Mavitas, O. Tasdemir, and K. Bayazit
Effects of Pregnancy on Long-Term Follow-Up of Mitral Valve Bioprostheses
Asian Cardiovasc Thorac Ann, September 1, 1998; 6(3): 174 - 178.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 by The Society of Thoracic Surgeons.